Health Condition 1: null- Clinically diagnosed localized, plaque psoriasis vulgaris or Palmoplanter psoriasis
Conditions
Interventions
Intervention1: Halobetasol propionate (0.05%) ointment: applied twice daily once in morning and other application in evening on the target lesion according to FTU (Finger Tip Unit) method for 14 days
Sponsors
Glenmark Pharmaceuticals Limited
Eligibility
Inclusion criteria
Inclusion criteria: 1. Subjects between 18 to 60 yrs ( treatment naïve patients or patients receiving treatments such as Corticosteroids, Methotrexate or PUVA should be given a wash out period of 10 days) 2. Clinically diagnosed localized, plaque psoriasis vulgaris or Palmoplanter psoriasis affecting maximum up to 10-20% of the total body surface area. The size of lesion selected is approximately 4 to 10 cm2 3. Subjects must provide written informed consent and comply to the protocol.
Exclusion criteria
Exclusion criteria: 1. Subjects with psoriatic erythroderma, generalized pustular psoriasis 2. Pregnancy & Lactation 3. Concomitant tuberculosis 4. Syphilis 5. Uncontrolled Diabetes mellitus 6. Leukemia
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Investigatorâ??s clinical assessment on LPSI score to evaluate reduction of erythema, scaling, thickness. 2. Assessment of Pruritus 3. Global Evaluation 4. Subjects observation Timepoint: 0day- 7days- 14 days | — |
Secondary
| Measure | Time frame |
|---|---|
| NILTimepoint: NIL | — |
Countries
India
Contacts
Public ContactDr Amanjit Ahluwalia
Glenmark pharmaceuticals ltd
Outcome results
None listed